Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma
暂无分享,去创建一个
N. Malats | A. Carrato | F. Real | A. Ploner | H. Renz | M. Löhr | X. Molero | W. Ye | M. Nilsson | M. Kordes | Jingru Yu | Maria Evangelina Lopez de Maturana | Lidia Estudillo Garcia
[1] N. Malats,et al. Deciphering the complex interplay between pancreatic cancer, diabetes mellitus subtypes and obesity/BMI through causal inference and mediation analyses , 2020, Gut.
[2] Lynette M. Smith,et al. Trefoil factor(s) and CA19.9: A promising panel for early detection of pancreatic cancer , 2019, EBioMedicine.
[3] G. Wang,et al. Expression and clinical significance of serum NT5E protein in patients with colorectal cancer. , 2019, Cancer biomarkers : section A of Disease markers.
[4] R. Sears,et al. Serum Biomarker Signature-Based Liquid Biopsy for Diagnosis of Early-Stage Pancreatic Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] M. Kamali-Moghaddam,et al. Plasma Protein Profiling Reveal Osteoprotegerin as a Marker of Prognostic Impact for Colorectal Cancer , 2018, Translational oncology.
[6] W. Bamlet,et al. Comparison of Fasting Human Pancreatic Polypeptide Levels Among Patients With Pancreatic Ductal Adenocarcinoma, Chronic Pancreatitis, and Type 2 Diabetes Mellitus , 2018, Pancreas.
[7] V. Torri,et al. Soluble stroma‐related biomarkers of pancreatic cancer , 2018, EMBO molecular medicine.
[8] C. Lang,et al. Epicardial adipose tissue is related to arterial stiffness and inflammation in patients with cardiovascular disease and type 2 diabetes , 2018, BMC Cardiovascular Disorders.
[9] Annelie Abrahamsson,et al. Equal Pro-inflammatory Profiles of CCLs, CXCLs, and Matrix Metalloproteinases in the Extracellular Microenvironment In Vivo in Human Dense Breast Tissue and Breast Cancer , 2018, Front. Immunol..
[10] F. Miller,et al. Pancreatic cancer screening , 2018, Abdominal Radiology.
[11] M. Makary,et al. Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers , 2017, Proceedings of the National Academy of Sciences.
[12] Tracey L Marsh,et al. A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer , 2017, Journal of the National Cancer Institute.
[13] B. Garcia,et al. Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers , 2017, Science Translational Medicine.
[14] S. Hanash,et al. Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. , 2016, Journal of the National Cancer Institute.
[15] J. Škrha,et al. Lower plasma levels of glucose-dependent insulinotropic peptide (GIP) and pancreatic polypeptide (PP) in patients with ductal adenocarcinoma of the pancreas and their relation to the presence of impaired glucoregulation and weight loss. , 2017, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].
[16] A. Jemal,et al. Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.
[17] B. Sitek,et al. Quantitative proteome analysis reveals the correlation between endocytosis-associated proteins and hepatocellular carcinoma dedifferentiation. , 2016, Biochimica et biophysica acta.
[18] J. Kere,et al. Variant Profiling of Candidate Genes in Pancreatic Ductal Adenocarcinoma. , 2015, Clinical Chemistry.
[19] S. Duffy,et al. Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma , 2015, Clinical Cancer Research.
[20] Suresh T. Chari,et al. Early Detection of Sporadic Pancreatic Cancer , 2015, Pancreas.
[21] Benjamin D. Smith,et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.
[22] S. Yachida,et al. Evolution and dynamics of pancreatic cancer progression , 2013, Oncogene.
[23] D. Radice,et al. The pitfalls of CA19-9: routine testing and comparison of two automated immunoassays in a reference oncology center. , 2012, American journal of clinical pathology.
[24] M. Nowak,et al. Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer , 2010, Nature.
[25] Tibor Schuster,et al. Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages , 2010, PLoS medicine.
[26] R. Abrams,et al. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Max Kuhn,et al. Building Predictive Models in R Using the caret Package , 2008 .
[28] K. Ohuchida,et al. S100A11, A Putative Tumor Suppressor Gene, Is Overexpressed in Pancreatic Carcinogenesis , 2006, Clinical Cancer Research.
[29] C. Compton,et al. AJCC Cancer Staging Manual , 2002, Springer New York.
[30] M. Raimondo,et al. Islet amyloid polypeptide is not a satisfactory marker for detecting pancreatic cancer. , 2001, Gastroenterology.
[31] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.